A Phase I/II Dose-Ranging, Pharmacokinetic, Drug Interaction, Safety and Preliminary Efficacy Study of Oral Clarithromycin Granules for Suspension, in Combination With Zidovudine or Dideoxyinosine, in the Treatment of Disseminated Mycobacterium Avium Complex Infections in Pediatric Patients With AIDS

Inclusion Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

- Prophylaxis treatment for Pneumocystis carinii pneumonia.

- Topical antivirals.

Prior Medication: Required:

- Zidovudine (AZT), 90 - 180 mg/m2 q6h, or didanosine (ddI), 60 - 120 mg/m2 q8h for 4
weeks prior to study entry.

Patients must have the following:

- Diagnosis of AIDS and Mycobacterium avium complex.

- Ability to tolerate therapy with zidovudine or didanosine at specified dosages.

- Written consent from a parent or legal guardian.

- Willing to comply with all procedures and scheduled visits. Relatively stable
clinical condition.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

- History of significant depressive disorder.

- History of allergy to macrolide antibiotics.

- Presence of acute bacterial infection or acute onset of opportunistic infection as
listed in protocol.

Patients with the following are excluded:

- Presence of current opportunistic infection other than Mycobacterium avium complex
defined as systemic candidemia, cryptosporidiosis, isosporiasis, toxoplasmosis,
pneumocystosis, salmonellosis, or acute bacterial infection.

Prior Medication:

Excluded within 30 days of study entry:

- Systemic antimycobacterial drugs, myelosuppressive drugs, nephrotoxic agents,
cytotoxic or experimental chemotherapy, or antiviral drugs.

Active alcohol or drug use sufficient in the opinion of the investigator to prevent
adequate compliance with medication regimen and clinic visits.